Dr. Curtis has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott, Centocor, Pfizer, and BMS, and (more than $10,000 each) from Amgen, Consortium of Rheumatology Researchers of North America, Roche/Genentech, and UCB.
Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis
Version of Record online: 27 SEP 2011
Copyright © 2011 by the American College of Rheumatology
Arthritis Care & Research
Volume 63, Issue 10, pages 1415–1424, October 2011
How to Cite
Kawai, V. K., Grijalva, C. G., Arbogast, P. G., Curtis, J. R., Solomon, D. H., Delzell, E., Chen, L., Ouellet-Hellstrom, R., Herrinton, L., Liu, L., Mitchel, E. F., Stein, C. M. and Griffin, M. R. (2011), Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis. Arthritis Care Res, 63: 1415–1424. doi: 10.1002/acr.20550
- Issue online: 27 SEP 2011
- Version of Record online: 27 SEP 2011
- Accepted manuscript online: 11 JUL 2011 10:27AM EST
- Manuscript Accepted: 27 JUN 2011
- Manuscript Received: 7 JAN 2011
- Agency for Healthcare Research and Quality. Grant Numbers: U18-HSO17919-01, R01HS018517
- NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. Grant Number: 5P60AR56116
- NIH. Grant Numbers: 5T32GM007569-33, AR053351
- 6Treatment of rheumatoid arthritis. In: Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS, editors. Kelley's textbook of rheumatology, vol II. 8th ed. Philadelphia: Saunders; 2008. p. 1119–68..
- 27Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43: 495–505., , , , , on behalf of the
- 37A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. Pain Med 2005; 6: 113–21., , , , , .